# A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)

> **NCT01513291** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 237 (actual)

## Conditions studied

- Migraine
- Headache

## Interventions

- **DRUG:** MK-6096
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01513291
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-06
- **Primary completion:** 2012-10-03
- **Final completion:** 2012-10-03
- **Target enrollment:** 237 (ACTUAL)
- **Last updated:** 2018-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01513291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01513291, "A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01513291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*